2016
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression
Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell 2016, 30: 432-443. PMID: 27593345, PMCID: PMC5154333, DOI: 10.1016/j.ccell.2016.08.002.Peer-Reviewed Original ResearchConceptsBladder cancer metastasisCancer metastasisLymph node metastasisPoor clinical outcomeTumor-associated macrophagesPrimary tumor growthPotential therapeutic targetOsteopontin expression correlatesNode metastasisClinical outcomesPrimary tumorCD44 axisTherapeutic targetTumor aggressivenessMetastasisTumor growthExpression correlatesTumor cellsRac-GEF Tiam1Osteopontin bindsMetastasis suppressionRac1 axisTumorsCD44RhoGDI2
2012
p21-Activated kinase 4 promotes prostate cancer progression through CREB
Park M, Lee H, Lee C, You S, Kim D, Park B, Kang M, Heo W, Shin E, Schwartz M, Kim E. p21-Activated kinase 4 promotes prostate cancer progression through CREB. Oncogene 2012, 32: 2475-2482. PMID: 22710715, DOI: 10.1038/onc.2012.255.Peer-Reviewed Original ResearchConceptsP21-activated kinase 4Prostate cancer progressionProstate cancerCancer progressionLNCaP-FGC cellsPromising therapeutic targetKinase 4Prostate cancer cellsDU145 prostate cancer cellsSpecific protein kinase A (PKA) inhibitorProtein kinase A (PKA) inhibitorElevation of cAMPNeuroendocrine differentiationNude miceTherapeutic targetActive PAK4Downstream effector pathwaysTumor progressionDecreased expressionTumor formationCancerCancer cellsPC-3ProgressionEffector pathways